Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors - Results of a Prospective Biomarker Study.

Forschner, Andrea; Weißgraeber, Stephanie; Hadaschik, Dirk; Schulze, Martin; Kopp, Maria; Kelkenberg, Sabine; Sinnberg, Tobias; Garbe, Claus; Biskup, Saskia; Battke, Florian

Forschner, Andrea; Weißgraeber, Stephanie; Hadaschik, Dirk; Schulze, Martin; Kopp, Maria; Kelkenberg, Sabine; Sinnberg, Tobias; Garbe, Claus; Biskup, Saskia; Battke, Florian.

Afiliación

Forschner A; Center for Dermatooncology, Department of Dermatology, University Hospital Tuebingen, Tuebingen, Germany.
Weißgraeber S; Center for Genomics and Transcriptomics (CeGaT) GmbH, Tuebingen, Germany.
Hadaschik D; Center for Genomics and Transcriptomics (CeGaT) GmbH, Tuebingen, Germany.
Schulze M; Practice for Human Genetics, Tuebingen, Germany.
Kopp M; Center for Genomics and Transcriptomics (CeGaT) GmbH, Tuebingen, Germany.
Kelkenberg S; Center for Genomics and Transcriptomics (CeGaT) GmbH, Tuebingen, Germany.
Sinnberg T; Center for Dermatooncology, Department of Dermatology, University Hospital Tuebingen, Tuebingen, Germany.
Garbe C; Center for Dermatooncology, Department of Dermatology, University Hospital Tuebingen, Tuebingen, Germany.
Biskup S; Center for Genomics and Transcriptomics (CeGaT) GmbH, Tuebingen, Germany.
Battke F; Practice for Human Genetics, Tuebingen, Germany.

Onco Targets Ther ; 13: 5017-5032, 2020.

Article en En | MEDLINE | ID: mdl-32581559

Palabras clave

BRAF and MEK inhibition; circulating tumor DNA; ctDNA; metastatic melanoma

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Onco Targets Ther Año: 2020 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Nueva Zelanda

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google